PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak Syndrome

News Godzilla
Copyright 2021 novcog.com news network We rock so you don''t have to.


PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak Syndrome PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak Syndrome

The study shows a promising path to treating idiopathic systemic capillary leak syndrome (ISCLS, also known as Clarkson disease) and vascular-related rare diseases The unique Tie2-activating antibody program PMC-403 demonstrates efficacy in improving survival and reducing vascular leakage in preclinical ISCLC models DAEJEON, South Korea, November 22, 2023 /PRNewswire/ — PharmAbcine Inc. (KOSDAQ:..
previous post